Global warming didn't give Malia Obama asthma

[timslash]

USA Today Columnist Goes Where GMA Would Not With Air 62 Pct. Cleaner Look at Obama Himself As Possible Cause For Malia s Asthma
A Wednesday "Good Morning America" piece gave President Barack Obama an open mic to claim that, in ABC's words, "climate change became a personal issue for him when his older daughter Malia, now 16, was rushed to the emergency room with an asthma attack when she was just a toddler." Somehow, ABC managed to avoid another possible contributor — besides the obvious possibility that Malia developed asthma independent of external influences — namely the President's 30-year smoking habit. He is said to have quit once and for all in 2011. USA Today columnist James S. Robbins wasn't impressed with the President's "reasoning," and with good cause, as he articulated in a Thursday evening column. He even managed to get a "there's been no warming for a long time" observation past USA Today's editors (links are in original; bolds are mine):
>Obama blames global warming for his daughter's asthma and showed his incompetence and lack of education again...
And he also, magically forget about main cause of children asthma - smoking parents.

 

[Maxx]

It;s pathetic that he uses his kid's illness to push his fallacious political rhetoric.

 

[Stephanie]

Yep, he was a SMOKER. he caused her asthma to be worse.

Once a liar always a liar. Notice he has no problems Using his kids as props when he has an agenda

 

[Rexx Taylor]

Global Warming gave me violent diahrrea when I was 7.

 

[waltky]

Good gut bacteria helps the lungs too...

Study: Lack of 'Good' Bacteria May Put Babies at Higher Risk for Asthma
September 30, 2015 - New research shows that babies who lack certain "good" bacteria in their intestines in the first months of life may be at higher risk of asthma. The study, published Wednesday in the journal Science Translational Medicine, identified four specific bacteria that experts think may protect children from developing asthma.

In the study, researchers at the University of British Columbia tracked health records of 319 children from birth to age 3, and analyzed stool samples taken during infancy to check their gut bacteria. The first clue: There were 22 youngsters deemed very high risk because of early asthma warning signs — and at 3 months of age, all of them harbored much lower levels of the four specific gut bacteria than the other babies. That doesn't prove the missing bugs are protective.

Medical experts say asthma is on the rise in recent decades, particularity in Western nations.

But the researchers infected germ-free mice with an at-risk tot's stool sample alone, or with a supplement of the four "good'' bacteria. Restoring the missing bugs markedly reduced airway inflammation in the mice's offspring, they reported. Doctors are still unsure how these bacteria develop naturally in the immune system. But stool samples from one-year-olds didn't show much difference between the at-risk group and the rest, suggesting the first three months of life may be a critical time period, the researchers concluded. They speculated that cesarean section deliveries, antibiotics and use of formula instead of breast milk could have some effect on which good bacteria develop.

Wednesday's study raises the provocative possibility of one day altering tots' buildup of protective bugs, maybe through probiotics. "I want to emphasize that we're not ready for that yet,'' cautioned study co-author Dr. Stuart Turvey, a pediatric immunologist at the University of British Columbia and BC Children's Hospital. But a "vision for the future would be to prevent this disease.'' The British Columbia team has already begun testing samples from 500 more babies who are enrolled in a larger Canadian study exploring factors in the development of allergy and asthma. Medical experts say asthma is on the rise in recent decades, particularity in Western nations. The disease causes wheezing, breathing problems and coughing, and in some cases can be fatal.

Study: Lack of 'Good' Bacteria May Put Babies at Higher Risk for Asthma

 

[waltky]

Price cut wins approval of drug...

GSK biotech asthma drug wins UK approval after extra price cut
December 1, 2016 - GlaxoSmithKline's new injectable asthma drug Nucala has been recommended for use in Britain's state-run health service in the most severe patients, after the drugmaker provided further analyses on its use and made an additional price cut.

The National Institute for Health and Care Excellence (NICE) initially declined to endorse the antibody treatment as evidence presented by GSK suggested it would be used in less severe cases and would not be cost effective.

The latest draft guidance from NICE, published on Thursday, now backs the medicine for the sickest patients with high levels of white blood cells called eosinophils. The U.S. Food and Drug Administration made a similar ruling earlier in the month. The drug is designed to lower the level of eosinophils, too many of which can cause lung inflammation.

Nucala is given by injection every four weeks. Its list cost is 840 pounds ($1,050) per dose but the price the National Health Service will pay is confidential. NICE is also appraising Teva Pharmaceutical Industries' rival biotech drug Cinqaero for severe eosinophilic asthma and has asked Teva to provide more information on cost-effectiveness.

GSK biotech asthma drug wins UK approval after extra price cut